Proactive and Reactive Therapeutic Drug Monitoring of Biologic Therapies in Inflammatory Bowel Disease Are Complementary, Not Mutually Exclusive
- PMID: 29555230
- DOI: 10.1016/j.cgh.2017.11.033
Proactive and Reactive Therapeutic Drug Monitoring of Biologic Therapies in Inflammatory Bowel Disease Are Complementary, Not Mutually Exclusive
Comment in
-
Reply.Clin Gastroenterol Hepatol. 2018 Apr;16(4):598-599. doi: 10.1016/j.cgh.2017.12.030. Clin Gastroenterol Hepatol. 2018. PMID: 29555231 No abstract available.
Comment on
-
Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab.Clin Gastroenterol Hepatol. 2017 Oct;15(10):1580-1588.e3. doi: 10.1016/j.cgh.2017.03.031. Epub 2017 Mar 30. Clin Gastroenterol Hepatol. 2017. PMID: 28365486 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
